
This study assesses the clinical and economic implications from a payer perspective of human papillomavirus genotyping for cervical cancer screening in comparison with existing practices.
This study assesses the clinical and economic implications from a payer perspective of human papillomavirus genotyping for cervical cancer screening in comparison with existing practices.
Published: March 1st 2016 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.